Eikon Therapeutics, Inc.

Aug 26, 2026

▼ -2.3%today

Eikon Therapeutics to Participate in Investor Conferences in September 2026

Eikon Therapeutics, a late-stage clinical biopharmaceutical company, announced participation in two investor conferences in September 2026. CEO Roger M. Perlmutter and CFO Freddie Bowie will present at the Cantor Global Healthcare Conference and the Morgan Stanley Global Healthcare Conference. The company focuses on developing innovative oncology therapies to meet significant medical needs.

Aug 18, 2026

Eikon Therapeutics to Participate in KOL Event on Therapeutic Use of PARP Inhibitors in Oncology Hosted by Cantor Fitzgerald

Eikon Therapeutics will participate in a KOL event on August 20, 2026, hosted by Cantor Fitzgerald. CEO Roger M. Perlmutter will join Dr. Timothy A. Yap, an expert in PARP inhibitors, to discuss their therapeutic use in various cancers. The event aims to shed light on the current landscape and limitations of PARP inhibitors.

Aug 13, 2026

▲ +7%on this newsshared move

Eikon Therapeutics Reports Second Quarter 2026 Financial Results and Provides Clinical Updates

Eikon Therapeutics reported its Q2 2026 financial results, highlighting significant advancements in its oncology pipeline. The company announced seven abstracts accepted for the ESMO Congress, showcasing promising clinical data for EIK1001 and EIK1003. Eikon ended the quarter with a robust cash position of $531.2 million, enabling continued support for its clinical programs despite a net loss of $88.4 million.

Aug 11, 2026

▲ +5.1%on this newsshared move

Eikon Therapeutics Announces Dose Selection for TeLuRide-006, an Ongoing Adaptive Phase 2/3 Trial of EIK1001 in Advanced Melanoma

Eikon Therapeutics has announced the selection of a 0.60 mg/m² dose for the TeLuRide-006 trial, which is part of an ongoing adaptive Phase 2/3 study of EIK1001 in patients with advanced melanoma. This decision follows a recommendation from the independent Data Monitoring Committee, indicating confidence in the trial's design and direction.

Aug 10, 2026

Eikon Therapeutics Appoints Johnny Bennett, Ph.D. to its Scientific Advisory Board

Eikon Therapeutics has appointed Dr. Johnny Bennett to its Scientific Advisory Board. Dr. Bennett, currently Vice President at Merck Research Laboratories, brings significant expertise in medicinal chemistry and drug discovery. His addition is expected to enhance Eikon's research priorities and strengthen its collaboration with Merck, particularly in oncology-focused drug development.

Eikon Therapeutics Announces First Patient Dosed in TeLuRide-008, a Registrational Phase 2/3 Trial of EIK1001 in Non-Small Cell Lung Cancer

Eikon Therapeutics has initiated dosing in the TeLuRide-008 trial, evaluating EIK1001 for stage 4 Non-Small Cell Lung Cancer. This Phase 2/3 study combines EIK1001 with pembrolizumab and chemotherapy, aiming to enhance immune responses. The trial represents a crucial step in addressing the unmet needs of NSCLC patients, with EIK1001 showing promise in earlier studies.

Jul 20, 2026

Eikon Therapeutics Announces Seven Abstracts Accepted for Presentation at the 2026 European Society of Medical Oncology (ESMO) Congress

Eikon Therapeutics announced the acceptance of seven abstracts for the 2026 ESMO Congress in Madrid. The presentations will cover updates from their clinical pipeline, including data from ongoing Phase 1/2 and Phase 2 trials of various drug candidates targeting advanced cancers. This highlights Eikon's commitment to developing innovative therapies for unmet medical needs.

Jun 25, 2026

▲ +16.2%on this news· ran to +29% by day 1

Eikon Therapeutics to Join the Russell 3000® Index

Eikon Therapeutics, a late-stage clinical biopharmaceutical company, announced its inclusion in the Russell 3000 Index, effective June 26, 2026. This addition highlights Eikon's growth and commitment to developing innovative medicines for serious medical needs, particularly in oncology. The Russell 3000 Index represents a significant portion of the US equity market, providing a benchmark for investors.

Jun 8, 2026

Eikon Therapeutics Announces the Appointment of Ma. Fatima D. Francisco to its Board of Directors

Eikon Therapeutics has appointed Ma. Fatima D. Francisco as an independent director on its Board, effective June 15, 2026. Francisco, who has a notable background in leadership from Procter & Gamble, will also serve on the Compensation Committee. Her expertise is expected to enhance Eikon's efforts in developing innovative medicines for serious unmet medical needs.

Jun 1, 2026

Q2 Company Update June 2026 Disclaimer Any statements made in this presentation that are not statements of historical fact, including statements about our beliefs and expectations, are forward-looking statements and shou

Eikon's Q2 Company Update outlines the progress of its clinical pipeline and highlights upcoming milestones for 2026. The FDA has sanctioned the transition to a Phase 2/3 registrational trial, with EIK1001 demonstrating efficacy in preliminary trials. However, the company is facing significant net losses and requires additional funding to support continued operations. Risks also include potential development failures and legal complications that could impact their future prospects.

May 31, 2026

Efficacy, safety and cytokine profiling with addition of the toll-like receptor (TLR) 7/8 dual agonist EIK1001 to Standard of Care First-Line Therapy: the Phase 2 TeLuRide-005 trial in Stage 4 Non-Small Cell Lung Cancer – Poster Presentation, ASCO 2026

The Phase 2 TeLuRide-005 trial evaluates the efficacy and safety of EIK1001, a TLR 7/8 dual agonist, when added to standard first-line therapy for Stage 4 Non-Small Cell Lung Cancer. The results were presented at ASCO 2026, highlighting promising data that could impact treatment protocols.

May 31, 2026

Adaptive Phase 2/3 Study of EIK1001, a TLR7/8 Dual Agonist, in Combination with Pembrolizumab, as First-Line Therapy in Participants with Advanced Melanoma (TeLuRide-006) – Poster Presentation, ASCO 2026

The article discusses the Adaptive Phase 2/3 study of EIK1001, a TLR7/8 dual agonist, in combination with Pembrolizumab for treating advanced melanoma. This study, known as TeLuRide-006, is set to be presented at ASCO 2026. The research aims to evaluate the effectiveness of this combination therapy as a first-line treatment option.

May 31, 2026

A Phase 2/3 Study of EIK1001 in Combination with Pembrolizumab and Chemotherapy in Participants with Stage 4 Non-Small Cell Lung Cancer (TeLuRide-008) – Poster Presentation, ASCO 2026

The article discusses a Phase 2/3 study of EIK1001 combined with pembrolizumab and chemotherapy for treating Stage 4 non-small cell lung cancer. This study, referred to as TeLuRide-008, will be presented as a poster at ASCO 2026. The research aims to evaluate the effectiveness of this combination therapy in improving patient outcomes.

May 30, 2026

A Multicenter, Multi-Part, Phase 1/2 Study of EIK1005 as Monotherapy and in Combination with Pembrolizumab in Participants with Advanced Solid Tumors, Including Participants with Microsatellite Instability High (MSI-H) or Mismatch Repair Deficient (dMMR) Tumors – Poster Presentation, ASCO 2026

The article discusses a Phase 1/2 study of EIK1005, both as a standalone treatment and in combination with Pembrolizumab, targeting advanced solid tumors. The study focuses on patients with microsatellite instability high (MSI-H) or mismatch repair deficient (dMMR) tumors. The findings were presented at ASCO 2026, highlighting the potential of EIK1005 in oncology.

May 30, 2026

EIK1003, a PARP1-selective inhibitor, in combination with paclitaxel (PTX): Initial combination and updated monotherapy results from a Phase 1/2 study EIK1003-001 in advanced solid tumors – Poster Presentation, ASCO 2026

The article discusses the initial combination and updated monotherapy results of EIK1003, a PARP1-selective inhibitor, in a Phase 1/2 study (EIK1003-001) for advanced solid tumors. The findings were presented at ASCO 2026, highlighting the potential effectiveness of EIK1003 when used alongside paclitaxel. This research could pave the way for new treatment options in oncology.

May 30, 2026

Eikon Therapeutics Presents Data on Clinical-Stage Programs at the 2026 Annual Meeting of the American Society of Clinical Oncology

Eikon Therapeutics presented updated data on its clinical-stage programs at the 2026 ASCO Annual Meeting. The Phase 2 trial of EIK1001 in stage 4 NSCLC showed promising response rates and tolerability. Additionally, EIK1003 demonstrated safety and efficacy as a monotherapy and in combination with paclitaxel for advanced solid tumors, reinforcing the potential of Eikon's innovative therapies.

May 22, 2026

Eikon Therapeutics Announces Availability of Six Abstracts for Presentation at the 2026 Annual Meeting of the American Society of Clinical Oncology

Eikon Therapeutics announced the acceptance of six abstracts for presentation at the 2026 ASCO Annual Meeting. These abstracts showcase clinical progress in their oncology pipeline, including trials for EIK1001, EIK1003, and EIK1005. The presentations will highlight both monotherapy and combination strategies aimed at optimizing treatment for advanced cancers.

May 11, 2026

Eikon Therapeutics Reports First Quarter 2026 Financial Results and Provides Clinical Updates

Eikon Therapeutics reported its first quarter 2026 financial results, highlighting a strong cash position of $596 million and continued progress in its oncology pipeline. The company focuses on three key programs: EIK1001, EIK1003, and EIK1005, with significant data to be presented at the upcoming ASCO annual meeting. Despite a net loss of $83 million, Eikon remains optimistic about its clinical advancements and financial outlook.

Apr 22, 2026

Rapid Optimization Enabled by Single-Molecule Tracking: Discovery of a Potent RUVBL1/2 Inhibitor to Evaluate the Targeting of MYC-Driven Cancers

The article discusses the discovery of a potent RUVBL1/2 inhibitor through a Single-Molecule Tracking (SMT) approach, which enhances drug discovery by providing robust potency measurements. This inhibitor shows improved efficacy in a MYC-dependent Burkitt lymphoma xenograft model, indicating its potential in targeting MYC-driven cancers. The study highlights SMT's role in optimizing drug discovery campaigns.

Mar 30, 2026

Eikon Therapeutics Announces Fourth Quarter and Full Year 2025 Financial Results and Provides Clinical and Corporate Updates

Eikon Therapeutics reported its fourth quarter and full year 2025 financial results, highlighting a successful IPO that raised $381 million. The company completed enrollment in the Phase 2 TeLuRide-005 trial for EIK1001 in lung cancer. Despite significant net losses and rising expenses, Eikon is advancing its clinical programs and expects to fund operations into 2027.

Mar 30, 2026

Eikon Therapeutics Announces Fourth Quarter and Full Year 2025 Financial Results and Provides Clinical and Corporate Updates Closed upsized initial public offering in February 2026, raising $381 million in gross proceeds

Eikon Therapeutics announced its fourth quarter and full year 2025 financial results, highlighting a successful $381 million IPO. The company reported significant progress in its clinical programs, particularly with EIK1001 and next-generation PARP inhibitors. Despite these advancements, Eikon faces considerable challenges, including substantial net losses and increased operational expenses. The firm is optimistic about its future, leveraging its strengthened financial position to pursue further development of its innovative therapies.

Feb 4, 2026

Eikon Therapeutics Announces Pricing of Upsized Initial Public Offering

Eikon Therapeutics has announced the pricing of its upsized initial public offering, offering 21,177,600 shares at $18.00 each. The offering is expected to generate approximately $381 million in gross proceeds. Eikon's common stock will begin trading on the Nasdaq under the ticker symbol 'EIKN' on February 5, 2026. The offering is subject to customary closing conditions.

Dec 2, 2025

Eikon Therapeutics Announces the Election of David W. Meline to its Board of Directors

Eikon Therapeutics has elected David W. Meline as an independent director, effective November 23, 2025. Meline, former CFO at Moderna and Amgen, brings significant financial and operational expertise to the board. His appointment is expected to enhance Eikon's strategic growth as the company advances its drug discovery initiatives.

Oct 15, 2025

Eikon Therapeutics to Present New Phase 2 Data on EIK1001 in First-Line Non-Small Cell Lung Cancer at ESMO 2025

Eikon Therapeutics will present new Phase 2 data on EIK1001 at the ESMO Congress 2025. The study evaluates EIK1001, a TLR7/8 co-agonist, in combination with pembrolizumab and chemotherapy for stage 4 non-small cell lung cancer. The results aim to demonstrate improved patient outcomes and support the progression to a Phase 2/3 trial.

May 29, 2025

Eikon Therapeutics to Share Clinical Data and Program Updates at the 2025 ASCO Annual meeting

Eikon Therapeutics will present new clinical data and program updates at the ASCO Annual Meeting from May 30 to June 3, 2025. The presentations will include safety and efficacy data from their selective PARP1 inhibitor EIK1003 and updates on their other oncology programs. Eikon has also entered a collaboration with Merck for a clinical trial involving EIK1001.

Feb 26, 2025

Eikon Therapeutics Secures $350.7 Million Series D to Advance Clinical-Stage Programs and Future Pipeline

Eikon Therapeutics has announced the closing of a $350.7 million Series D financing round, led by existing investors and including new participants. This funding will support the advancement of its clinical-stage programs, particularly EIK1001 for advanced melanoma, and other promising therapies in development. The company aims to leverage its innovative drug discovery technologies to accelerate the development of new medicines.

Feb 19, 2025

Oblique line scan illumination enables expansive, accurate and sensitive single-protein measurements in solution and in living cells

The article discusses a new technique called oblique line scan illumination, which allows for expansive, accurate, and sensitive measurements of single proteins both in solution and within living cells. This advancement could significantly enhance the study of protein dynamics and interactions in biological systems.

Feb 19, 2025

Eikon Therapeutics Announces Nature Methods Publication Highlighting its Pioneering Oblique Line Scan Technology

Eikon Therapeutics has published a paper in Nature Methods showcasing its innovative Oblique Line Scan (OLS) technology, which enhances its Single Molecule Tracking (SMT) platform. This technology allows for high-throughput analysis of protein dynamics, significantly improving the understanding of cellular processes and drug interactions. Eikon's advancements aim to accelerate drug discovery and provide deeper insights into fundamental biology.

Jan 7, 2025

Eikon Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Eikon Therapeutics will present at the 43rd Annual J.P. Morgan Healthcare Conference on January 13, 2025. CEO Roger M. Perlmutter will discuss recent clinical development progress and advancements in research programs. This presentation underscores the company's commitment to accelerating drug discovery and development.

Nov 20, 2024

Eikon Therapeutics Announces Appointment of Michael Klobuchar as Chief Operating Officer

Eikon Therapeutics has appointed Michael A. Klobuchar as Chief Operating Officer. Klobuchar, previously at Merck, will oversee corporate infrastructure and strategic alignment as Eikon enters a growth phase. His extensive experience in various sectors will support the company's mission to advance drug discovery and development. Eikon aims to leverage innovative technologies for therapeutic advancements.

Nov 18, 2024

Discovery and Development of EIK1003, a Potent and Selective PARP1 Inhibitor | EORTC 2024 Poster Presentation

The article discusses the discovery and development of EIK1003, a potent and selective PARP1 inhibitor. This compound is set to be presented at the EORTC 2024 conference, indicating a significant advancement in cancer treatment research. The focus on PARP1 inhibition suggests promising therapeutic applications.

Aug 26, 2024

Eikon Therapeutics Management to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference

Eikon Therapeutics will present a business update at the Morgan Stanley 22nd Annual Global Healthcare Conference on September 4, 2024. CEO Roger M. Perlmutter and CFO Alfred Bowie will discuss recent advancements in the company's pipeline and clinical development programs. The presentation can be accessed by interested parties via an audio recording.

Jul 20, 2024

SPT-derived estrogen receptor dynamics predicts therapeutic effects in clinical compounds | CSHL Poster Presentation

The article discusses a poster presentation at CSHL focusing on SPT-derived estrogen receptor dynamics. This research aims to predict the therapeutic effects of clinical compounds, potentially influencing future treatment approaches. The findings could contribute to a better understanding of estrogen receptors in therapeutic contexts.

Jul 18, 2024

WRN inhibition leads to its chromatin-associated degradation via the PIAS4-RNF4-p97/VCP axis

The article discusses a study revealing that the inhibition of WRN leads to its degradation associated with chromatin through the PIAS4-RNF4-p97/VCP axis. This discovery suggests potential therapeutic applications, particularly in cancer treatment. The identification of this novel degradation pathway could pave the way for innovative strategies in targeting WRN.

Jun 6, 2024

Eikon Therapeutics to Present at the 45th Annual Goldman Sachs Global Healthcare Conference

Eikon Therapeutics will present at the 45th Annual Goldman Sachs Global Healthcare Conference on June 12, 2024. CEO Roger M. Perlmutter and CFO Alfred Bowie will discuss the company's pipeline and clinical development progress. The presentation aims to showcase Eikon's innovative approaches in drug discovery.

Jun 5, 2024

Optimized Properties and Synthesis of Photoactivatable Diazoketorhodamines Facilitate and Enhance High-Throughput Single-Molecule Tracking

The article discusses advancements in the properties and synthesis of photoactivatable diazoketorhodamines. These improvements are designed to enhance high-throughput single-molecule tracking, potentially benefiting various research applications. The optimized compounds promise to facilitate more efficient tracking in molecular studies.

May 28, 2024

Eikon Therapeutics Announces Multiple Abstracts to be Presented at the American Society of Clinical Oncology (ASCO) Annual Meeting

Eikon Therapeutics announced multiple abstracts for the 2024 ASCO Annual Meeting, showcasing its clinical-stage programs EIK1001 and EIK1003. An oral presentation will highlight the safety and preliminary efficacy of EIK1001 in combination with pembrolizumab, while three poster presentations will cover EIK1001's combinations with pembrolizumab and atezolizumab, as well as a Phase 1 study of EIK1003. The event will take place in Chicago from May 31 to June 4, 2024.

May 13, 2024

A high-throughput platform for single-molecule tracking identifies drug interaction and cellular mechanisms

A new high-throughput platform has been developed for single-molecule tracking, which aims to identify drug interactions and elucidate cellular mechanisms. This innovative technology could significantly advance research in drug development and cellular biology. The platform promises to provide deeper insights into how drugs interact at the molecular level.

May 1, 2024

High Throughput SMT Provides Insight Across Diverse Areas of Cell Biology | CSHL 2024 Poster Presentation

The article announces a poster presentation at CSHL 2024, highlighting the capabilities of High Throughput SMT in providing insights across various fields of cell biology. This innovative approach is expected to contribute significantly to research and understanding in the area. The event aims to showcase advancements in the technology and its applications.

Apr 12, 2024

Eikon Therapeutics Presents Pharmacokinetic/Biomarker Analysis of the Toll-Like Receptor 7 and 8 (TLR7/8) Agonist EIK1001 at the Annual Meeting of the American Association for Cancer Research

Eikon Therapeutics presented findings on EIK1001's pharmacokinetics and biomarker data at the AACR Annual Meeting. The analysis from two Phase 1 trials indicated a linear and dose-proportional PK profile, with dose-dependent increases in IP-10 and IFNg, aligning with the drug's mechanism of action. These results support future trial designs and dose optimization.

Jan 8, 2024

Eikon Therapeutics to Provide Corporate Updates at the 42nd Annual J.P. Morgan Healthcare Conference

Eikon Therapeutics announced significant updates at the 42nd Annual J.P. Morgan Healthcare Conference, including the advancement of EIK1001 into Phase 2 trials for lung cancer and the enrollment of patients in a Phase 1 trial for EIK1003, a selective PARP1 inhibitor. The company also initiated IND-enabling studies for a brain-penetrant PARP1 inhibitor and established a new business unit focused on proprietary technology. Eikon anticipates identifying additional clinical candidates in early 2024.

Jan 4, 2024

Exclusive: Roger Perlmutter on the biggest problem in Big Pharma, leaving Merck, and building Eikon

Roger Perlmutter, former head of R&D at Merck, has transitioned to CEO of Eikon Therapeutics shortly after leaving Merck. At Eikon, he is focused on building advanced microscopes and developing new drugs, positioning the company as a significant player in the biopharma industry.

Jan 3, 2024

Roger Perlmutter lights up the biological dark, building a new pharma force in Eikon and its superpowered microscopes

Eikon aims to revolutionize drug discovery by using advanced microscopy to observe cellular mechanics at the protein level. This innovative approach seeks to identify and tackle challenging drug targets in real-time, leveraging Nobel Prize-winning technology on an industrial scale. The company's efforts could significantly impact the biopharmaceutical landscape.

Dec 18, 2023

Eikon Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Eikon Therapeutics, a biotechnology company, will present at the 42nd Annual J.P. Morgan Healthcare Conference on January 8, 2024. CEO Roger M. Perlmutter will update attendees on the company's pipeline and clinical development progress. Eikon focuses on enhancing drug discovery through advanced engineering and proprietary technologies.

Dec 4, 2023

Eikon Therapeutics Announces the Election of Robert L. Huffines to its Board of Directors

Eikon Therapeutics has appointed Robert L. Huffines as an independent director, effective December 1, 2023. Huffines, who has over 30 years of experience in investment banking at J.P. Morgan Chase, is expected to provide valuable insights to enhance Eikon's growth. His expertise in life sciences and commitment to bioethics will support the company's mission to develop transformative medicines.